0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......


Basic View | Expanded View
 Showing 1-20 of 33 Articles
Viewpoint 
Daniel Gold, DO; David E. Newman-Toker, MD, PhD; Joshua M. Sharfstein, MD
This Viewpoint reports on the effect of the Affordable Care Act on US health care, specifically with regard to neurology.
Editorial 
Steven Vernino, MD, PhD
Myasthenia gravis (MG) is the prototypic autoimmune neurological disorder. Weakness and muscle fatigue in MG result from an autoimmune attack on the neuromuscular junction, which causes a failure of neuromuscular transmission.1 The autoimmune nature of the disease was initially proposed in 1960, and in the 1970s, serum antibodies against the ...
Original Investigation 
Rodrigo P. Almeida, BS; Stephanie A. Schultz, BS; Benjamin P. Austin, PhD; Elizabeth A. Boots, BS; N. Maritza Dowling, PhD; Carey E. Gleason, PhD; Barbara B. Bendlin, PhD; Mark A. Sager, MD; Bruce P. Hermann, PhD; Henrik Zetterberg, MD, PhD; Cynthia M. Carlsson, MD, MS; Sterling C. Johnson, PhD; Sanjay Asthana, MD; Ozioma C. Okonkwo, PhD

Importance  Although advancing age is the strongest risk factor for the development of symptomatic Alzheimer disease (AD), recent studies have shown that there are individual differences in susceptibility to age-related alterations in the biomarkers of AD pathophysiology.

Objective  To investigate whether cognitive reserve (CR) modifies the ...

Original Investigation 
Pedro M. Rodríguez Cruz, MD, MSc; Michal Al-Hajjar, MD; Saif Huda, MB, ChB; Leslie Jacobson, DPhil; Mark Woodhall, PhD; Sandeep Jayawant, FRCPH; Camilla Buckley, MRCP, DPhil; David Hilton-Jones, MD, FRCP; David Beeson, PhD; Angela Vincent, FMedSci, FRS; Maria Isabel Leite, MD, DPhil; Jacqueline Palace, DM

Importance  Cell-based assays (CBAs) were shown to improve detection of acetylcholine receptor (AChR) antibodies in patients with myasthenia gravis (MG). Herein, we asked whether these assays were able to help determine the diagnosis in patients studied in routine clinical practice.

Objectives  To determine the diagnostic usefulness ...

Editorial: Unraveling the Enigma of Seronegative Myasthenia Gravis; Steven Vernino, MD, PhD
Review 
Michael D. Fox, MD, PhD; Ron L. Alterman, MD
Includes: Supplemental Content

Importance  Dystonia is a heterogeneous neurologic disorder characterized by abnormal muscle contractions for which standard medical therapy is often inadequate. For such patients, therapeutic brain stimulation is becoming increasingly used.

Objectives  To review the evidence and effect sizes for treating different types of dystonia with different ...

Original Investigation 
Avi Gadoth, MD; Beatrice Nefussy, PhD; Margalit Bleiberg, PhD; Tirza Klein, MD; Irena Artman, MD; Vivian E. Drory, MD

Importance  Celiac disease is an autoimmune disorder triggered by gluten in genetically predisposed individuals. Gluten sensitivity can cause neurologic manifestations, such as ataxia or neuropathy, with or without gastrointestinal symptoms. Many patients with gluten ataxia produce antibodies toward the newly identified neuronal transglutaminase 6 (TG6). Two case ...

Original Investigation 
Jie Ding, PhD; Sigurdur Sigurdsson, MSc; Melissa Garcia, MPH; Caroline L. Phillips, MS; Gudny Eiriksdottir, MSc; Vilmundur Gudnason, MD, PhD; Mark A. van Buchem, MD, PhD; Lenore J. Launer, PhD
Includes: Supplemental Content

Importance  The spatial distribution of cerebral microbleeds (CMBs), which are asymptomatic precursors of intracerebral hemorrhage, reflects specific underlying microvascular abnormalities of cerebral amyloid angiopathy (lobar structures) and hypertensive vasculopathy (deep brain structures). Relatively little is known about the occurrence of and modifiable risk factors for developing CMBs, ...

Original Investigation 
Rawan Tarawneh, MD; Denise Head, PhD; Samantha Allison, MA; Virginia Buckles, PhD; Anne M. Fagan, PhD; Jack H. Ladenson, PhD; John C. Morris, MD; David M. Holtzman, MD
Includes: Supplemental Content

Importance  Measures of neuronal loss are likely good surrogates for clinical and radiological disease progression in Alzheimer disease (AD). Cerebrospinal fluid (CSF) markers of neuronal injury or neurodegeneration may offer usefulness in predicting disease progression and guiding outcome assessments and prognostic decisions in clinical trials of disease-modifying ...

Review 
Michael Joseph Howell, MD; Carlos Hugh Schenck, MD

Importance  The dream enactment of rapid eye movement sleep behavior disorder (RBD) is often the first indication of an impending α-synuclein disorder, such as Parkinson disease, multiple-system atrophy, or dementia with Lewy bodies.

Objective  To provide an overview of RBD from the onset of dream enactment ...

Editorial 
Venkatesh Aiyagari, MBBS, DM; Michael N. Diringer, MD
The last decade has witnessed significant advances in the management of patients with cardiac arrest (CA), resulting in improvement in survival and functional outcome. An analysis of data from the Cardiac Arrest Registry to Enhance Survival, a prospective registry of patients with out-of-hospital CA, found that risk-adjusted rates of survival ...
Editorial 
Roger N. Rosenberg, MD; Ronald C. Petersen, PhD, MD
The message of this Editorial is simple and straightforward. For the past decade or more, billions of dollars have been invested by the pharmaceutical industry and the National Institutes of Health (NIH) to develop effective therapies for Alzheimer disease. Despite these vast sums of money, an effective therapy to delay ...
Original Investigation  FREE
Tobias Cronberg, MD, PhD; Gisela Lilja, OT; Janneke Horn, MD, PhD; Jesper Kjaergaard, MD, DMSci; Matt P. Wise, MD, DPhil; Tommaso Pellis, MD; Jan Hovdenes, MD, PhD; Yvan Gasche, MD, PhD; Anders Åneman, MD, PhD; Pascal Stammet, MD; David Erlinge, MD, PhD; Hans Friberg, MD, PhD; Christian Hassager, MD, DMSci; Michael Kuiper, MD, PhD; Michael Wanscher, MD, PhD; Frank Bosch, MD, PhD; Julius Cranshaw, MD, PhD; Gian-Reto Kleger, MD; Stefan Persson, MD; Johan Undén, MD, PhD; Andrew Walden, MD, PhD; Per Winkel, MD, DMSci; Jørn Wetterslev, MD, PhD; Niklas Nielsen, MD, PhD; for the TTM Trial Investigators
Includes: Supplemental Content

Importance  Brain injury affects neurologic function and quality of life in survivors after cardiac arrest.

Objective  To compare the effects of 2 target temperature regimens on long-term cognitive function and quality of life after cardiac arrest.

Design, Setting, and Participants  In this multicenter, international, parallel ...

Editorial: Targeted Temperature Management; Venkatesh Aiyagari, MBBS, DM; Michael N. Diringer, MD
Original Investigation 
Michela Ripolone, PhD; Dario Ronchi, PhD; Raffaella Violano, BS; Dionis Vallejo, MD; Gigliola Fagiolari, BS; Emanuele Barca, MD; Valeria Lucchini, PhD; Irene Colombo, MD; Luisa Villa, MD; Angela Berardinelli, MD; Umberto Balottin, MD; Lucia Morandi, MD; Marina Mora, BS; Andreina Bordoni, BS; Francesco Fortunato, BS; Stefania Corti, PhD; Daniela Parisi, BS; Antonio Toscano, MD; Monica Sciacco, PhD; Salvatore DiMauro, MD; Giacomo P. Comi, MD; Maurizio Moggio, MD
Includes: Supplemental Content

Importance  The important depletion of mitochondrial DNA (mtDNA) and the general depression of mitochondrial respiratory chain complex levels (including complex II) have been confirmed, implying an increasing paucity of mitochondria in the muscle from patients with types I, II, and III spinal muscular atrophy (SMA-I, -II, and ...

Original Investigation 
Daniel A. Nation, PhD; Emily C. Edmonds, PhD; Katherine J. Bangen, PhD; Lisa Delano-Wood, PhD; Blake K. Scanlon, PhD; S. Duke Han, PhD; Steven D. Edland, PhD; David P. Salmon, PhD; Douglas R. Galasko, MD; Mark W. Bondi, PhD; for the Alzheimer’s Disease Neuroimaging Initiative Investigators
Includes: Supplemental Content

Importance  Increased pulse pressure associated with age-related arterial stiffening increases risk for Alzheimer dementia but the mechanism responsible for this association remains unclear.

Objectives  To determine the relationship between pulse pressure and cerebral spinal fluid biomarker profiles of preclinical Alzheimer disease, investigate whether observed relationships are ...

Original Investigation 
Jon B. Toledo, MD; Maria Bjerke, PhD; Xiao Da, MS; Susan M. Landau, PhD; Norman L Foster, MD; William Jagust, MD; Clifford Jack Jr, MD; Michael Weiner, MD; Christos Davatzikos, PhD; Leslie M. Shaw, PhD; John Q. Trojanowski, MD, PhD; for the Alzheimer’s Disease Neuroimaging Initiative Investigators
Includes: Supplemental Content

Importance  Cerebrospinal fluid (CSF) and positron emission tomographic (PET) amyloid biomarkers have been proposed for the detection of Alzheimer disease (AD) pathology in living patients and for the tracking of longitudinal changes, but the relation between biomarkers needs further study.

Objective  To determine the association between ...

Clinical Implications of Basic Neuroscience Research 
Oren J. Zarnett, BSc; Arjun Sahgal, MD; Jessica Gosio; James Perry, MD; Mitchel S. Berger, MD; Susan Chang, MD; Sunit Das, MD, PhD
Includes: Supplemental Content

Importance  Despite improvements in survival with aggressive chemoradiation, outcomes for patients diagnosed as having glioblastoma multiforme (GBM) remain poor. Survival is further limited in elderly patients, who are often unable to tolerate multimodality therapy. The appropriate treatment approach for elderly patients (aged >65 years) with GBM remains ...

JAMA Neurology Clinical Challenge 
Lawrence S. Honig, MD, PhD
Editorial 
Pravin Khemani, MD; Richard B. Dewey Jr, MD
Parkinson disease (PD) is known to affect multiple neurotransmitter systems, resulting in both motor and nonmotor symptoms. Pain is an underrecognized but important nonmotor symptom of PD that may be very disabling and is known to impair quality of life.1 While significant progress has been made in ameliorating motor symptoms ...
Original Investigation 
Yu Jin Jung, MD; Han-Joon Kim, MD, PhD; Beom S. Jeon, MD, PhD; Hyeyoung Park, MD; Woong-Woo Lee, MD; Sun Ha Paek, MD, PhD
Includes: Supplemental Content

Importance  Pain is a common and distressing feature in Parkinson disease (PD). The major indication of subthalamic nucleus deep brain stimulation (STN DBS) is motor complications in advanced PD; however, pain reduction after STN DBS has been noted.

Objective  To evaluate the long-term effect of STN ...

Editorial: Subthalamic Nucleus Deep Brain Stimulation; Pravin Khemani, MD; Richard B. Dewey Jr, MD

Sign in

Purchase Options

• Subscribe to the journal

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts